Schedule

Update on Severe Asthma 2021

DATE: THURSDAY AND Friday, March 25-26, 2021

LOCATION: Live On-Line (with recorded presentations available for 1 month following the course)

For additional information, call Chris Fanta at 617-732-4353

Print Version-PDF

MARCH 25, 2021 – Day 1: Understanding Asthma

9:25-9:30  a.m. Welcome and introduction E. Israel, C. Fanta
9:30 – 10:05 Genetic Diseases and Airway Obstruction B. Raby
10:05 – 10:40 Severe Asthma in the Age of Corona Virus and Racial Injustice M. Louisias
10:40—11:15 Occupational Exposures and Severe Asthma R. McCunney
11:15 – 12:00 Workshop A: Microbiome and the Development of Asthma
Workshop B: Vitamin D, Lung Development, & the Origins of Asthma
Workshop C: Lipoxins and Severe Asthma
K. Lee‐Sarwar
S. Weiss
B. Levy
12:00 – 12:30 Case Discussions: Diagnostic Dilemmas Panel
Break
2:30-3:05 Obesity and Asthma A. Dixon
3:05 – 3:40 Asthma in Schools W. Phipatanakul
Special Consideration
3:40-4:15 ABPA and Eosinophilic Lung Disease J. Boyce
4:15-5:00 Guest Lecture: Update from the European U-BIOPRED
Asthma Research Consortium
S.-E Dahlén

MARCH 26, 2021 – DAY 2: TREATING ASTHMA

9:30-10:05  a.m. Evaluation of Severe Asthma: A Systematic Approach N. Barrett
10:05 – 10:40 Insights from the GINA and NAEPP Asthma Guidelines C. Fanta
10:40 – 11:15 Choosing Among the Biologics for Severe Asthma E. Israel
11:15—11:50 Stepping‐Up Care in Children with Severe Asthma K. Haver
11:50 – 12:30 Workshop D: Gastroesophageal Reflux and Severe Asthma
Workshop E: Laryngeal Disordered Breathing Mimicking
Severe Asthma
Workshop F: Treating Rhinosinusitis and Nasal Polyposis

W. Chan
T. Carroll & L. Gordon

A. Maxfield

Break
2:30-3:05 Aspirin‐Exacerbated Respiratory Disease T. Laidlaw
3:05 – 3:50 Bronchial Thermoplasty: Pro and Con S.Majid and E. Israel
3:50-4:25 Novel Therapies: A Look into the Future E. Israel
4:25-5:00 Case Discussions: Therapeutic Dilemmas Panel

Accreditation:

ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE PRACTITIONERS and REGISTERED NURSES

For the purpose of recertification, the American Academy of Nurse Practitioners Certification Board and American Nurses Credentialing Center accept AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education). We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.

PHYSICIAN ASSISTANTS

The National Commission on Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification. We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.

CANADIAN ACCREDITATION

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

DISCLOSURE POLICY

Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.